NFT
RXRX icon

Nan Fung Trinity’s Recursion Pharmaceuticals RXRX Stock Holding History

Nan Fung Trinity’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-69,323
Closed -$284K – 79
2025
Q4 		$284K Hold
69,323
– – 0.02% 77
2025
Q3 		$338K Buy
+69,323
New +$364K 0.03% 70

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nan Fung Trinity's RXRX Position: Q1 2026 in Review

Nan Fung Trinity sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 69,323 shares — an estimated $284K sold.

Nan Fung Trinity first reported a position in RXRX in Q3 2025 and held it in 2 quarters. The position peaked at $338K in Q3 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Nan Fung Trinity reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nan Fung Trinity sold 69,323 Recursion Pharmaceuticals shares in Q1 2026, an estimated $284K.
  • Nan Fung Trinity first reported a position in Recursion Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Nan Fung Trinity's Recursion Pharmaceuticals position peaked at $338K in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Nan Fung Trinity's 13F filing for Q1 2026, filed 5 May 2026.